Related Experiment Video
Updated: Feb 12, 2026

New Thrombectomy Technique for Total Portal Vein Thrombosis in Liver Transplantation
Published on: June 27, 2025
Pediatric cirrhotic cardiomyopathy: Impact on liver transplant outcomes
Norman Junge1, Claudia Junge2, Julian Schröder1
1Paediatric Gastroenterology and Hepatology.
Insights
Cirrhotic cardiomyopathy in pediatric liver transplant candidates causes mild, reversible cardiac changes, particularly with cholestasis. These changes can affect transplant care but do not impact survival.
Area of Science:
- Cardiology
- Hepatology
- Pediatric Gastroenterology
Background:
- Cirrhotic cardiomyopathy (CCM) is common in adults awaiting liver transplantation.
- Data on cardiac changes in pediatric liver transplant (pLT) candidates, especially comparing cirrhotic to non-cirrhotic liver disease, is limited.
Purpose of the Study:
- To evaluate cardiac changes in pediatric liver transplant candidates with cirrhotic liver disease.
- To compare cardiac findings between cirrhotic and non-cirrhotic pediatric liver disease.
- To assess the reversibility of cardiac changes after pLT.
Main Methods:
- Retrospective analysis of 198 pediatric liver transplant candidates (median age 4.1 years).
- Echocardiography and 12-lead electrocardiogram assessments before and 12 months after pLT.
- Correlation of cardiac findings with liver fibrosis and cholestasis stages.
Main Results:
- Cirrhotic patients showed significantly higher left ventricular end-diastolic diameter (LVIDd) z score, left ventricular mass z score, and mass index compared to non-cirrhotic patients.
- Pathological LVIDd z scores were more frequent in cirrhotic patients and associated with cholestasis.
- All cardiac changes, including pathological LVIDd z scores, were reversible 1 year after pLT and correlated with longer ICU stay but not survival.
- Prolonged QTc time was not associated with liver cirrhosis in this cohort.
Conclusions:
- Pediatric liver transplant candidates with cirrhotic liver disease exhibit frequent, mild, and reversible cardiac changes, linked to cholestasis.
- These CCM-associated changes can influence peritransplant care and hospitalization duration.
- Further prospective studies are needed to investigate QTc prolongation factors and potential benefits of ursodeoxycholic acid.
Abstract:
In adults, cirrhotic cardiomyopathy (CCM) has a significant incidence and impact on liver transplantation. For pediatric liver transplantation (pLT), data on liver-induced cardiac changes are scarce, and in particular, the comparison between cirrhotic and noncirrhotic liver disease has not been investigated. We retrospectively evaluated cardiac changes associated with CCM by echocardiography and 12-lead electrocardiogram in 198 pLT-candidates (median age 4.1 years) 4.2 before and 12 months after pLT. Results were correlated with the stage of liver fibrosis and cholestasis before transplantation. The left ventricular end-diastolic diameter (LVIDd) z score, left ventricular mass z score, and left ventricular mass index were significantly higher in cirrhotic patients (-0.10 versus 0.98, P < 0.001; -1.55 versus -0.42, P = 0.001; 78.99 versus 125.64 g/m2 , P = 0.001, respectively) compared with children with noncirrhotic liver disease. Pathological z scores (>2SDS) for the LVIDd occurred more frequently in cirrhotic patients compared with patients with noncirrhotic liver disease (31/169 versus 1/29; P = 0.03) and were significantly associated with cholestasis. All observed cardiac changes were reversible 1 year after pLT. Pathological LVIDd z scores correlated highly with intensive care unit (ICU) stay (9.6 days versus 17.1 days, respectively, P = 0.002) but not with patient survival pre-LT or post-LT. In contrast to other studies, prolonged QTc time was not associated with liver cirrhosis in our patients. In conclusion, CCM-associated cardiac changes in pLT candidates with cirrhotic liver disease are frequent, mild, and associated with cholestasis and reversible after pLT. They may impact peritransplant care and posttransplant hospitalization time. Further prospective evaluation is warranted. In particular, for QTc time prolongation etiological factors, possible protective effects of ursodeoxycholic acid treatment and the use as a screening parameter for CCM should be verified. Liver Transplantation 24 820-830 2018 AASLD.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy VI: Nursing Management

